If you've landed here because you keep hearing the word "peptides" and aren't quite sure what it means, you're in good company. A Reddit thread from early 2026 titled "What's up with the peptides hype?" collected nearly 600 upvotes from people asking exactly the same question. One commenter put it well: "Never heard this word before, now it's seemingly everywhere like AI."
This guide starts from the beginning — the biology, the categories, the evidence landscape, and the practical questions you should ask before considering any peptide compound.
The basic biology — what a peptide actually is
A peptide is a short chain of amino acids — the same molecules that make up proteins. The difference is size: proteins are long, complex structures (typically 100+ amino acids) that perform structural and enzymatic roles throughout the body. Peptides are shorter chains, typically 2 to 50 amino acids, that function primarily as biological signals — molecules that tell specific cells to do specific things.
Your body produces thousands of peptides naturally. Insulin, the hormone that regulates blood sugar, is a 51-amino acid peptide. Growth hormone is a 191-amino acid peptide. Oxytocin — the "bonding hormone" — is a 9-amino acid peptide. The GLP-1 hormone that regulates appetite after eating is a peptide. These aren't exotic compounds — they're fundamental to how your body functions every day.
Peptides are attractive as pharmaceutical targets because they're highly specific — they bind to particular receptors and trigger particular responses without broadly disrupting other systems. They're also generally well-tolerated because they're structurally similar to compounds the body already produces. The challenge is that many degrade quickly in the gut, which is why so many require injection rather than oral dosing.
When a pharmaceutical company or researcher synthesises a peptide in a laboratory, they're creating a version of something that already exists in nature — or a modified version designed to be more stable, more potent, or longer-acting than the natural compound. Semaglutide, for example, is a modified version of the natural GLP-1 hormone, engineered to have a much longer half-life so it can be dosed once weekly rather than being broken down within minutes like the natural hormone.
The two very different worlds of peptides
This is the most important distinction to understand — and the one most popular coverage gets wrong by conflating them.
FDA-approved peptide drugs
More than 80 peptide-based drugs have been approved by the FDA. These have gone through Phase 1, 2, and 3 clinical trials involving thousands of human participants over years or decades. They have known safety profiles, established dosing guidelines, and medical monitoring protocols. They require prescriptions.
The GLP-1 class is the most prominent current example. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are peptide drugs with more human clinical trial data than almost any compounds in the history of pharmacology. Tesamorelin (Egrifta) is a peptide drug FDA-approved for lipodystrophy. PT-141 (Vyleesi) is a peptide drug FDA-approved for sexual dysfunction. Insulin — used by tens of millions of people daily — is a peptide drug.
Research-grade peptide compounds
This is an entirely different category — and the one generating most of the 2026 cultural conversation. These are compounds sold as "research chemicals" or "for research use only," not approved for human therapeutic use by the FDA. They exist in a regulatory grey area: legal to purchase and possess in most US states, but not approved for human consumption.
BPC-157, GHK-Cu, TB-500, Epithalon, Semax, Ipamorelin, CJC-1295 — these are research-grade compounds. Some have extensive preclinical datasets — hundreds of animal studies with compelling mechanistic data. Some have limited human pilot data. Almost none have completed the rigorous Phase 3 clinical trial process that FDA-approved drugs require.
The success of FDA-approved peptides like semaglutide does not mean research-grade compounds work similarly. They're in the same broad chemical category but have almost nothing else in common in terms of evidence quality, regulatory oversight, or known safety profiles. The logical leap — "GLP-1s work, therefore BPC-157 works" — has been described as "unfounded" by leading longevity researchers. Mechanism is not the same as proven clinical effect.
How peptides work as biological signals
Peptides function by binding to specific receptors on cell surfaces — like a key fitting a lock. Each peptide has a particular molecular shape that allows it to bind to particular receptors, triggering a downstream cascade of biological effects. The specificity is what makes them interesting as research targets: a well-characterised peptide can activate a precise biological pathway without broadly disrupting other systems the way many conventional small-molecule drugs do.
The range of pathways that different peptides interact with is enormous. Some regulate appetite via gut hormone signalling (GLP-1 agonists). Some stimulate growth hormone release from the pituitary gland (ipamorelin, CJC-1295). Some modulate immune function via T-cell activation (thymosin alpha-1). Some promote tissue repair by driving new blood vessel formation (BPC-157 via VEGF upregulation). Some appear to reset gene expression patterns in aging cells (GHK-Cu via modulation of 4,000+ genes). Some activate telomerase — the enzyme that extends telomeres (Epithalon).
This breadth is why peptides attract research interest across such different domains — weight management, athletic recovery, skin aging, cognitive enhancement, and longevity research are all areas where specific peptide compounds are being actively studied.
Why peptides became a mainstream topic in 2026
Several forces converged simultaneously to push peptides from specialist circles into mainstream health culture.
The GLP-1 halo effect is the most important driver. The extraordinary commercial success of Ozempic and Wegovy — generating a combined $45+ billion in revenue in 2024 — put the word "peptide" into the cultural vocabulary for the first time at scale. When people discovered that the drugs helping millions lose significant weight were peptides, a logical but scientifically flawed inference followed: if peptide drugs work this well, other peptides must too. Biologically, this reasoning doesn't hold — but it explains the demand surge across every peptide category.
The FDA's 2023 decision to restrict 19 widely used research peptides from compounding pharmacies had an effect largely opposite to its intention. Rather than reducing use, it pushed demand underground and into the grey market, with peptide imports from Chinese synthesis facilities estimated at $328 million in 2025. The February 2026 announcement by HHS Secretary RFK Jr. that approximately 14 of those 19 compounds would return to legal compounding status generated another major wave of mainstream coverage and search interest.
Social media accelerated everything. TikTok videos tagged with "peptides" exceeded 50 million views by early 2026. The compounds that went most viral — GHK-Cu, BPC-157, the GLOW/KLOW blend — did so primarily through before-and-after skin and injury recovery content, not through scientific literature. The "Wolverine Stack" (BPC-157 + TB-500) became a mainstream cultural reference.
The evidence landscape — what's proven and what isn't
The peptide research world spans an enormous quality range. Being clear about that range is the single most important thing for making informed decisions.
At the top of the evidence hierarchy sit the FDA-approved peptide drugs — semaglutide, tirzepatide, tesamorelin, PT-141 — with thousands of patients across multiple Phase 3 randomised controlled trials. These represent some of the most rigorously tested compounds in modern medicine.
Below that are research compounds with substantial preclinical datasets and limited but existing human data. BPC-157 has 180+ animal studies but only a handful of small, poorly controlled human studies — no randomised placebo-controlled trials exist. GHK-Cu has 200+ studies across skin, wound healing, and gene expression — including controlled human trials for topical use — but limited injectable human data. Epithalon has 20+ years of research from the Khavinson Institute with human cohort data, but limited independent Western replication.
At the lower end of the evidence spectrum are compounds with mostly preliminary preclinical data and minimal human evidence — FOXO4-DRI, Dihexa, some newer mitochondrial peptides. These are genuinely early-stage research compounds where the gap between community enthusiasm and available evidence is at its largest.
Every compound page on this site includes a research depth indicator and distinguishes explicitly between animal data, pilot human studies, and randomised controlled trial evidence. We consider evidence quality the most important signal — mechanism is far less important than proof that the mechanism produces the claimed effects in humans. A compound with a compelling mechanism and only animal data is fundamentally different from one with Phase 3 human trial results.
Why most peptides require injection
One of the first practical questions people ask is why most peptides require injection rather than a pill. The answer is straightforward chemistry: digestive enzymes in the gut break down most peptide chains before they can reach systemic circulation in meaningful concentrations. The same biological process that digests dietary protein would degrade most therapeutic peptides before they could have any effect.
Subcutaneous injection — just below the skin, not into muscle — bypasses the gut entirely and delivers the compound directly into systemic circulation. This is why insulin has always required injection and why most research peptides are administered the same way.
There are meaningful exceptions. BPC-157 in its arginate salt form has documented oral activity, specifically relevant to gut tissue where concentrations following oral dosing are highest. Semax and Selank are delivered as nasal sprays, absorbed through nasal mucosa. MK-677 is technically a small molecule rather than a peptide and is orally bioavailable. Topical peptides — GHK-Cu serums, Argireline creams, Matrixyl formulations — work through skin absorption for localised effects and have the most accessible entry point for most people.
The sourcing problem — the most underappreciated practical risk
For FDA-approved peptide drugs, sourcing is straightforward — a prescription, a licensed pharmacy, a regulated product with verified contents. For research-grade compounds, sourcing quality is the most significant practical concern in the entire space and is consistently underestimated by new users.
Because research peptides aren't subject to pharmaceutical manufacturing regulations, quality control varies enormously across suppliers. FDA testing of online peptide products found up to 40% contained incorrect dosages, and nearly 25% contained undeclared compounds not listed on the label. The majority of grey-market product originates from Chinese synthesis facilities with no independent verification of purity or identity.
The minimum standard for any research peptide sourcing is a current Certificate of Analysis (COA) from an independent third-party laboratory — a document confirming the compound's identity, purity percentage, and concentration. Without this, there is no reliable way to know what's actually in a vial. Reputable suppliers make COAs publicly available or provide them before purchase, batch-matched to specific product lots.
Where to start on this site
The 26 compound pages cover the most researched peptides in depth — mechanisms, evidence quality, dosing context, community experience, and common stacks. If you're new to the space, the most useful starting points are compounds with the strongest human evidence bases:
If you're researching a specific goal, these articles go deeper on the evidence for particular use cases: